Copyright Reports & Markets. All rights reserved.

Global CGRP Monoclonal Antibodies Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of CGRP Monoclonal Antibodies by Type
    • 1.3.1 Overview: Global CGRP Monoclonal Antibodies Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global CGRP Monoclonal Antibodies Consumption Value Market Share by Type in 2025
    • 1.3.3 Eptinezumab
    • 1.3.4 Fremanezumab
    • 1.3.5 Galcanezumab
    • 1.3.6 Erenumab
  • 1.4 Global CGRP Monoclonal Antibodies Market by Application
    • 1.4.1 Overview: Global CGRP Monoclonal Antibodies Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Hospital
    • 1.4.3 Specialty Clinic
    • 1.4.4 Others
  • 1.5 Global CGRP Monoclonal Antibodies Market Size & Forecast
  • 1.6 Global CGRP Monoclonal Antibodies Market Size and Forecast by Region
    • 1.6.1 Global CGRP Monoclonal Antibodies Market Size by Region: 2021 VS 2025 VS 2032
    • 1.6.2 Global CGRP Monoclonal Antibodies Market Size by Region, (2021-2032)
    • 1.6.3 North America CGRP Monoclonal Antibodies Market Size and Prospect (2021-2032)
    • 1.6.4 Europe CGRP Monoclonal Antibodies Market Size and Prospect (2021-2032)
    • 1.6.5 Asia-Pacific CGRP Monoclonal Antibodies Market Size and Prospect (2021-2032)
    • 1.6.6 South America CGRP Monoclonal Antibodies Market Size and Prospect (2021-2032)
    • 1.6.7 Middle East & Africa CGRP Monoclonal Antibodies Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Lundbeck
    • 2.1.1 Lundbeck Details
    • 2.1.2 Lundbeck Major Business
    • 2.1.3 Lundbeck CGRP Monoclonal Antibodies Product and Solutions
    • 2.1.4 Lundbeck CGRP Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Lundbeck Recent Developments and Future Plans
  • 2.2 Alder Therapeutics
    • 2.2.1 Alder Therapeutics Details
    • 2.2.2 Alder Therapeutics Major Business
    • 2.2.3 Alder Therapeutics CGRP Monoclonal Antibodies Product and Solutions
    • 2.2.4 Alder Therapeutics CGRP Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Alder Therapeutics Recent Developments and Future Plans
  • 2.3 Teva
    • 2.3.1 Teva Details
    • 2.3.2 Teva Major Business
    • 2.3.3 Teva CGRP Monoclonal Antibodies Product and Solutions
    • 2.3.4 Teva CGRP Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Teva Recent Developments and Future Plans
  • 2.4 Pfizer Inc.
    • 2.4.1 Pfizer Inc. Details
    • 2.4.2 Pfizer Inc. Major Business
    • 2.4.3 Pfizer Inc. CGRP Monoclonal Antibodies Product and Solutions
    • 2.4.4 Pfizer Inc. CGRP Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Pfizer Inc. Recent Developments and Future Plans
  • 2.5 Lilly Inc.
    • 2.5.1 Lilly Inc. Details
    • 2.5.2 Lilly Inc. Major Business
    • 2.5.3 Lilly Inc. CGRP Monoclonal Antibodies Product and Solutions
    • 2.5.4 Lilly Inc. CGRP Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Lilly Inc. Recent Developments and Future Plans
  • 2.6 Daiichi Sankyo Co., Ltd.
    • 2.6.1 Daiichi Sankyo Co., Ltd. Details
    • 2.6.2 Daiichi Sankyo Co., Ltd. Major Business
    • 2.6.3 Daiichi Sankyo Co., Ltd. CGRP Monoclonal Antibodies Product and Solutions
    • 2.6.4 Daiichi Sankyo Co., Ltd. CGRP Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Daiichi Sankyo Co., Ltd. Recent Developments and Future Plans
  • 2.7 Amgen Inc.
    • 2.7.1 Amgen Inc. Details
    • 2.7.2 Amgen Inc. Major Business
    • 2.7.3 Amgen Inc. CGRP Monoclonal Antibodies Product and Solutions
    • 2.7.4 Amgen Inc. CGRP Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Amgen Inc. Recent Developments and Future Plans
  • 2.8 Novartis International AG
    • 2.8.1 Novartis International AG Details
    • 2.8.2 Novartis International AG Major Business
    • 2.8.3 Novartis International AG CGRP Monoclonal Antibodies Product and Solutions
    • 2.8.4 Novartis International AG CGRP Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Novartis International AG Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global CGRP Monoclonal Antibodies Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of CGRP Monoclonal Antibodies by Company Revenue
    • 3.2.2 Top 3 CGRP Monoclonal Antibodies Players Market Share in 2025
    • 3.2.3 Top 6 CGRP Monoclonal Antibodies Players Market Share in 2025
  • 3.3 CGRP Monoclonal Antibodies Market: Overall Company Footprint Analysis
    • 3.3.1 CGRP Monoclonal Antibodies Market: Region Footprint
    • 3.3.2 CGRP Monoclonal Antibodies Market: Company Product Type Footprint
    • 3.3.3 CGRP Monoclonal Antibodies Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global CGRP Monoclonal Antibodies Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global CGRP Monoclonal Antibodies Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global CGRP Monoclonal Antibodies Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global CGRP Monoclonal Antibodies Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America CGRP Monoclonal Antibodies Consumption Value by Type (2021-2032)
  • 6.2 North America CGRP Monoclonal Antibodies Market Size by Application (2021-2032)
  • 6.3 North America CGRP Monoclonal Antibodies Market Size by Country
    • 6.3.1 North America CGRP Monoclonal Antibodies Consumption Value by Country (2021-2032)
    • 6.3.2 United States CGRP Monoclonal Antibodies Market Size and Forecast (2021-2032)
    • 6.3.3 Canada CGRP Monoclonal Antibodies Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico CGRP Monoclonal Antibodies Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe CGRP Monoclonal Antibodies Consumption Value by Type (2021-2032)
  • 7.2 Europe CGRP Monoclonal Antibodies Consumption Value by Application (2021-2032)
  • 7.3 Europe CGRP Monoclonal Antibodies Market Size by Country
    • 7.3.1 Europe CGRP Monoclonal Antibodies Consumption Value by Country (2021-2032)
    • 7.3.2 Germany CGRP Monoclonal Antibodies Market Size and Forecast (2021-2032)
    • 7.3.3 France CGRP Monoclonal Antibodies Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom CGRP Monoclonal Antibodies Market Size and Forecast (2021-2032)
    • 7.3.5 Russia CGRP Monoclonal Antibodies Market Size and Forecast (2021-2032)
    • 7.3.6 Italy CGRP Monoclonal Antibodies Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific CGRP Monoclonal Antibodies Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific CGRP Monoclonal Antibodies Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific CGRP Monoclonal Antibodies Market Size by Region
    • 8.3.1 Asia-Pacific CGRP Monoclonal Antibodies Consumption Value by Region (2021-2032)
    • 8.3.2 China CGRP Monoclonal Antibodies Market Size and Forecast (2021-2032)
    • 8.3.3 Japan CGRP Monoclonal Antibodies Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea CGRP Monoclonal Antibodies Market Size and Forecast (2021-2032)
    • 8.3.5 India CGRP Monoclonal Antibodies Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia CGRP Monoclonal Antibodies Market Size and Forecast (2021-2032)
    • 8.3.7 Australia CGRP Monoclonal Antibodies Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America CGRP Monoclonal Antibodies Consumption Value by Type (2021-2032)
  • 9.2 South America CGRP Monoclonal Antibodies Consumption Value by Application (2021-2032)
  • 9.3 South America CGRP Monoclonal Antibodies Market Size by Country
    • 9.3.1 South America CGRP Monoclonal Antibodies Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil CGRP Monoclonal Antibodies Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina CGRP Monoclonal Antibodies Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa CGRP Monoclonal Antibodies Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa CGRP Monoclonal Antibodies Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa CGRP Monoclonal Antibodies Market Size by Country
    • 10.3.1 Middle East & Africa CGRP Monoclonal Antibodies Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey CGRP Monoclonal Antibodies Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia CGRP Monoclonal Antibodies Market Size and Forecast (2021-2032)
    • 10.3.4 UAE CGRP Monoclonal Antibodies Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 CGRP Monoclonal Antibodies Market Drivers
  • 11.2 CGRP Monoclonal Antibodies Market Restraints
  • 11.3 CGRP Monoclonal Antibodies Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 CGRP Monoclonal Antibodies Industry Chain
  • 12.2 CGRP Monoclonal Antibodies Upstream Analysis
  • 12.3 CGRP Monoclonal Antibodies Midstream Analysis
  • 12.4 CGRP Monoclonal Antibodies Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global CGRP Monoclonal Antibodies market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
    This report is a detailed and comprehensive analysis for global CGRP Monoclonal Antibodies market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global CGRP Monoclonal Antibodies market size and forecasts, in consumption value ($ Million), 2021-2032
    Global CGRP Monoclonal Antibodies market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
    Global CGRP Monoclonal Antibodies market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
    Global CGRP Monoclonal Antibodies market shares of main players, in revenue ($ Million), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for CGRP Monoclonal Antibodies
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global CGRP Monoclonal Antibodies market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Lundbeck, Alder Therapeutics, Teva, Pfizer Inc., Lilly Inc., Daiichi Sankyo Co., Ltd., Amgen Inc., Novartis International AG, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    CGRP Monoclonal Antibodies market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Eptinezumab
    Fremanezumab
    Galcanezumab
    Erenumab
    Market segment by Application
    Hospital
    Specialty Clinic
    Others
    Market segment by players, this report covers
    Lundbeck
    Alder Therapeutics
    Teva
    Pfizer Inc.
    Lilly Inc.
    Daiichi Sankyo Co., Ltd.
    Amgen Inc.
    Novartis International AG
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe CGRP Monoclonal Antibodies product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of CGRP Monoclonal Antibodies, with revenue, gross margin, and global market share of CGRP Monoclonal Antibodies from 2021 to 2026.
    Chapter 3, the CGRP Monoclonal Antibodies competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and CGRP Monoclonal Antibodies market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of CGRP Monoclonal Antibodies.
    Chapter 13, to describe CGRP Monoclonal Antibodies research findings and conclusion.

    Buy now